Targeted delivery of RNA therapies for Alzheimer's disease
Official title: Targeted Exosomal Delivery of siRNA Therapeutics for Neuroinflammatory Diseases
Funded at 3p Biotechnologies, INC. · NIH-10917679 · Data updated 2026-11-12
This study is exploring a new way to deliver special treatments directly to the brain to help fight Alzheimer's disease, using tiny particles from cow's milk to make sure the medicine gets to where it's needed most, which could lead to better care for people with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 3p Biotechnologies, INC. NIH-funded |
| Lab location | 1 site (Prospect, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $506,451 |
| NIH project number | 1R41AG084384-01A1 |
| Project ID | NIH-10917679 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neuroinflammatory conditions.
✕Less likely to help
Patients with neurodegenerative diseases not primarily driven by inflammation may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver small interfering RNA (siRNA) therapies specifically to the brain to combat neuroinflammatory diseases like Alzheimer's disease. By using exosomes derived from bovine colostrum, the researchers aim to enhance the delivery of siRNA that targets inflammatory processes in the brain. The approach involves a novel trans-spinal delivery method that could improve the effectiveness of treatments by ensuring that more of the therapeutic agent reaches the affected areas in the brain. This could potentially lead to better management of symptoms and progression of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by reducing inflammation in the brain.
How similar studies have gone: While the use of exosomes for drug delivery is a promising area of research, this specific approach targeting Alzheimer's disease is relatively novel and has not been extensively tested.
Where this research is happening
-
3p Biotechnologies, INC.
Prospect, United States Active
Researchers
- Principal investigator: Gupta, Ramesh C — 3p Biotechnologies, INC.
- Study coordinator: Gupta, Ramesh C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.